Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
0
조회
0
다운로드
1
인용
0
참고문헌
초록
Background/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67%vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea.
Abstract
Background/Aims: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. Methods: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. Results: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67%vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. Conclusions: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea.
참고문헌 (22)
- Smith KE, "Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team", N Engl J Med, 340, pp.1525~1532 (1999)
- Yang JR, "Pediatric campylobacteriosis in northern Taiwan from 2003 to 2005", BMC Infect Dis, 8, pp.151~ (2008)
- Steffen R, "Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica", JAMA, 281, pp.811~817 (1999)
- Seung-Hak Cho, "Enteric Bacteria Isolated from Acute Diarrheal Patients in the Republic of Korea between the Year 2004 and 2006", The Journal of Microbiology, 46(3), pp.325~330 (2008), 한국미생물학회
- Chong Y, "Korean Nationwide Surveillance of Antimicrobial Resistance of bacteria in 1997", Yonsei Med J, 39, pp.569~577 (1998)
- 이경원, "Increasing Prevalence of Vancomycin-Resistant Enterococci, and Cefoxitin-, Imipenem- and Fluoroquinolone-Resistant Gram-Negative Bacilli: a KONSAR Study in 2002", Yonsei Medical Journal, 45(4), pp.598~608 (2004), 연세대학교의과대학
- Descombe JJ, "Pharmacokinetic study of rifaximin after oral administration in healthy volunteers", Int J Clin Pharmacol Res, 14, pp.51~56 (1994)
- DuPont HL, "Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial", Clin Infect Dis, 33, pp.1807~1815 (2001)
- Adachi JA, "Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders", Clin Infect Dis, 42, pp.541~547 (2006)
- Taylor DN, "A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea", Am J Trop Med Hyg, 74, pp.1060~1066 (2006)
- Peña C, "Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections", Antimicrob Agents Chemother, 39, pp.520~524 (1995)
- Ena J, "Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones", Diagn Microbiol Infect Dis, 30, pp.103~107 (1998)
- Kim EC, "The analysis of antibiotics resistance 2008", Seoul National University Hospital Infection Control Newsletter, 15, pp.5~12 (2009)
- Cheong HJ, "Bacteremia due to quinolone-resistant Escherichia coli in ateaching hospital in South Korea", Clin Infect Dis, 33, pp.48~53 (2001)
- Lautenbach E, "Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections", Arch Intern Med, 162, pp.2469~2477 (2002)
- Robins GW, "Rifaximin: a review of its use in the management of traveller's diarrhoea", Drugs, 65, pp.1697~1713 (2005)
- Salix Pharmaceuticals, (2004), Salix Pharmaceuticals
- Martini S, "Solution structure of rifaximin and its synthetic derivative rifaximin OR determined by experimental NMR and theoretical simulation methods", Bioorg Med Chem, 12, pp.2163~2172 (2004)
- Jiang ZD, "In vitro activity and fecal concentration of rifaximin after oral administration", Antimicrob Agents Chemother, 44, pp.2205~2206 (2000)
- Brigidi P, "Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis", J Chemother, 14, pp.290~295 (2002)
- De Leo C, "Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin", Drugs Exp Clin Res, 12, pp.979~981 (1986)
- Guerrant RL, "Practice guidelines for the management of infectious diarrhea", Clin Infect Dis, 32, pp.331~351 (2001)